//
Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes
Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients
Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems
Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction"
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction
Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction